natgillin/translations-raw huggingface dataset:
10 ml (10 doses) 50 ml (50 doses) 100 ml (100 doses) 250 ml (250 doses) 12 x 10 ml (12 x 10 doses) 12 x 50 ml (12 x 50 doses) 12 x 100 ml (12 x 100 doses) 12 x 250 ml (12 x 250 doses) 
10 ml (10 odmerkov) 50 ml (50 odmerkov) 100 ml (100 odmerkov) 250 ml (250 odmerkov) 12 x 10 ml (12 x 10 odmerkov) 12 x 50 ml (12 x 50 odmerkov) 12 x 100 ml (12 x 100 odmerkov) 12 x 250 ml (12 x 250 odmerkov)
A mild and transient hyperthermia very commonly occurs on the day of vaccination. 
Na dan cepljenja se zelo pogosto pojavi blaga in prehodna hipertermija.
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product. 
Uredbe Komisije (EU) št. 37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št. 470/2009.
Not applicable. 
Niso znane.
Ingelvac MycoFLEX may be not authorised to use in certain Member States. 
Cepivo Ingelvac MycoFLEX v nekaterih državah članicah mogoče ni odobreno za uporabo.
Do not mix with any other veterinary medicinal product, except with Boehringer Ingelheim´s Ingelvac MycoFLEX (not for use in pregnant or lactating pigs). 
Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini, razen s cepivom Ingelvac MycoFLEX družbe Boehringer Ingelheim (mešanica ni za uporabo pri brejih ali doječih svinjah).
Ingelvac CircoFLEX suspension for injection for pigs 
Ingelvac CircoFLEX, suspenzija za injiciranje za prašiče
EXP {month/year} Once broached use immediately. 
EXP {mesec/leto} Odprto zdravilo uporabite takoj.
RP* 1.0-3.75 * Relative potency (ELISA test) by comparison with a reference vaccine 
* relativna učinkovitost (preskus ELISA) v primerjavi z referenčnim cepivom
Clear to slightly opalescent, colourless to yellowish suspension for injection. 
Bistra do rahlo opalescentna, brezbarvna do rumenkasta suspenzija za injiciranje.
QUANTITY OF THE ACTIVE SUBSTANCE 
KOLIČINA UČINKOVIN
10 ml (10 doses) 50 ml (50 doses) 
10 ml (10 odmerkov) 50 ml (50 odmerkov)
METHOD AND ROUTE OF ADMINISTRATION 
NAČIN IN POT UPORABE
During vaccination the uniformity of the coloured mixture should be monitored and maintained by continuous agitation. 
Med cepljenjem pazite, da bo barva mešanice enakomerna, vzdržujte jo s stalnim stresanjem.
Shelf life after first opening the bottle: use immediately. 
Rok uporabnosti po prvem odpiranju stične ovojnine: uporabite takoj.
• Cannot be administered in pregnant or lactating pigs. 
• Mešanice ne smete dajati brejim ali doječim svinjam.
Any unused mixture or waste material should be disposed according with local requirements. 
Morebitno neporabljeno mešanico ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Shelf life after first opening the immediate packaging: use immediately. 
Rok uporabnosti po prvem odpiranju vsebnika: uporabite takoj.
• Use the same volumes of Ingelvac CircoFLEX and Ingelvac MycoFLEX. 
• Uporabite enak volumen cepiv Ingelvac CircoFLEX in Ingelvac MycoFLEX.
One dose (1 ml) contains: Porcine circovirus type 2 ORF2 protein Carbomer 
En odmerek (1 ml) vsebuje: beljakovino ORF2 prašičjega cirkovirusa tipa 2 karbomer
To ensure appropriate mixing of the vaccines, gently shake the vaccine bottle of Ingelvac MycoFLEX until the mixture is of uniform orange to reddish colour. 
Nežno stresajte plastenko s cepivom Ingelvac MycoFLEX, dokler ni mešanica enakomerne oranžne do rdečkaste barve.
- After the transfer of the full content of Ingelvac CircoFLEX, disconnect and discard transfer needle and empty vaccine bottle of Ingelvac CircoFLEX. 
- Ko prenesete celotno vsebino plastenke cepiva Ingelvac CircoFLEX, odstranite z vsebnika iglo za prenos in prazno plastenko za cepivo Ingelvac CircoFLEX in ju zavrzite.
Administer one single injection dose (2 ml) of the mixture intramuscularly per pig, irrespective of body weight. 
Injicirajte en sam odmerek (2 ml) mešanice intramuskularno vsakemu prašiču, ne glede na telesno maso.
Pack sizes of 1 or 12 bottles of 10 ml (10 doses), 50 ml (50 doses), 100 ml (100 doses) or 250 ml (250 doses). 
Pakiranja vsebujejo 1 ali 12 steklenic po 10 ml (10 odmerkov), 50 ml (50 odmerkov), 100 ml (100 odmerkov) ali 250 ml (250 odmerkov).
100 ml (100 doses) 250 ml (250 doses) 
100 ml (100 odmerkov) 250 ml (250 odmerkov)
When mixed with Ingelvac MycoFLEX the following equipment should be used: 
Kadar nameravate cepivo zmešati s cepivom Ingelvac MycoFLEX, uporabite naslednjo opremo:
PARTICULARS TO APPEAR ON THE OUTER PACKAGE 10 ml; 50 ml, 100 ml, 250 ml cardboard box 
PODATKI NA ZUNANJI OVOJNINI 10 ml, 50 ml, 100 ml, 250 ml, kartonska škatla
PACKAGE LEAFLET: Ingelvac CircoFLEX suspension for injection for pigs 
NAVODILO ZA UPORABO Ingelvac CircoFLEX, suspenzija za injiciranje za prašiče
Porcine circovirus type 2 ORF2 protein 
beljakovino ORF2 prašičjega cirkovirusa tipa 2
Pack sizes of 1 or 12 high density polyethylene bottles of 10 ml, 50 ml, 100 ml or 250 ml. 
Pakiranja vsebujejo 1 ali 12 steklenicami iz polietilena velike gostote, ki vsebujejo po 10 ml, 50 ml, 100 ml ali 250 ml.
Special precautions to be taken by the person administering the veterinary medicinal product to animals 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Ni smiselno.
Carbomer Sodium chloride Water for injections 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi karbomer natrijev klorid voda za injekcije
When mixed with Ingelvac MycoFLEX: 
Kadar cepivo mešate s cepivom Ingelvac MycoFLEX:
Single intramuscular injection of one dose (1 ml), irrespective of body weight. 
Enkratni odmerek (1 ml) intramuskularno, ne glede na telesno maso.
Onset of immunity: 
Začetek imunosti :
Overdose (symptoms, emergency procedures, antidotes) Following the administration of a 4-fold overdose of vaccine no adverse reactions other than those described under section “Adverse reactions” have been observed. 
Po uporabi 4-kratnega prevelikega odmerka cepiva niso opazili drugih neželenih učinkov, razen tistih, ki so opisani v poglavju »Neželeni učinki«.
Name and address of the manufacturer responsible for batch release Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein 
Ime in naslov izdelovalca zdravila, odgovornega za sprostitev serije Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein
Single IM injection of 1 ml. 
odmerek 1 ml.
- Connect the opposite end of the transfer needle to the vaccine bottle of Ingelvac CircoFLEX. 
- Povežite drugi konec igle za prenos s plastenko s cepivom Ingelvac CircoFLEX.
Date of first authorisation: Date of last renewal: 
Datum pridobitve dovoljenja za promet: Datum podaljšanja dovoljenja za promet: 14.01.2013
Active substance: 
NAVEDBA UČINKOVIN
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Boehringer Ingelheim's Ingelvac MycoFLEX and administered at one injection site. 
Na voljo so podatki o varnosti in učinkovitosti, ki dokazujejo, da lahko to cepivo zmešamo s cepivom
If needed, gently press the vaccine bottle of Ingelvac CircoFLEX to facilitate the transfer. 
Če je treba, previdno stisnite plastenko s cepivom Ingelvac
SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY 
ZDRAVILA ALI ODPADNIH SNOVI, ČE OBSTAJAJO
- Transfer the Ingelvac CircoFLEX vaccine into the vaccine bottle of Ingelvac MycoFLEX. 
Povežite en konec igle za prenos s plastenko s cepivom, ki vsebuje Ingelvac MycoFLEX.
WITHDRAWAL PERIOD 
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
2621 North Belt Highway, 
Boehringer Ingelheim Animal Health USA Inc. 2621 North Belt Highway, St. Joseph, Missouri, 64506-2002 ZDA
This summary was last updated in 07-2017 
Povzetek je bil nazadnje posodobljen 07-2017.
(An 8-point improvement is considered clinically significant in this scale, which ranges from 0 to 100). 
(Izboljšanje za osem točk se po tej lestvici, ki sega od 0 do 100, šteje kot klinično pomembno.)
This was switched to a full marketing authorisation on 22 May 2017. 
To je bilo 22. maja 2017 spremenjeno v običajno dovoljenje za promet.
What measures are being taken to ensure the safe and effective use of Fampyra? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Fampyra?
The European Commission granted a conditional marketing authorisation valid throughout the European Union for Fampyra on 20 July 2011. 
Evropska komisija je pogojno dovoljenje za promet z zdravilom Fampyra, veljavno po vsej Evropski uniji, izdala 20. julija 2011.
The full EPAR for Fampyra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Fampyra je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The patients were treated for 9 or 14 weeks, with their waking speed measured along a 25 feet (7.5 metres) footpath. 
Bolnike so zdravili devet ali štirinajst tednov, njihovo hitrost hoje pa so merili na dolžini 25 čevljev (7,5 metra).
Fampyra is available as 10 mg tablets taken without food twice a day, 12 hours apart. 
Zdravilo Fampyra je na voljo v obliki 10-miligramskih tablet, ki se jemljejo brez hrane dvakrat na dan, v razmiku 12 ur.
Other information about Fampyra 
Druge informacije o zdravilu Fampyra
Treatment should also be stopped if a patient's walking ability worsens or if the patient does not report any benefit. 
Zdravljenje je treba prekiniti tudi, če se bolnikova sposobnost hoje poslabša ali če bolnik ne poroča o napredku.
After two to four weeks, patients are evaluated and those who have not shown an improvement should stop treatment. 
Po dveh do štirih tednih je treba bolnike oceniti in pri tistih, pri katerih ni izboljšanja, zdravljenje prekiniti.
As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full approval. 
Ker je družba predložila dodatne zahtevane podatke, je bilo dovoljenje za promet spremenjeno iz pogojnega v običajno.
This is a summary of the European public assessment report (EPAR) for Fampyra. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Fampyra.
With regard to the medicine's safety, serious side effects with Fampyra are rare. 
Kar zadeva varnost, so resni neželeni učinki zdravila Fampyra redki.
Fampyra was originally given ‘conditional approval' because there was more evidence to come about the medicine. 
Zdravilo Fampyra je prvotno pridobilo „pogojno dovoljenje za promet“, ker so bili pričakovani še dodatni dokazi o zdravilu.
What benefits of Fampyra have been shown in studies? 
Kakšne koristi je zdravilo Fampyra izkazalo v študijah?
Fampyra must not be used with other medicines that contain fampridine or medicines known as ‘inhibitors of organic cation transporter 2' such as cimetidine. 
Zdravila Fampyra se ne sme uporabljati sočasno z drugimi zdravili, ki vsebujejo fampridin, ali zdravili, znanimi kot „zaviralci organskih kationskih prenašalcev 2“, kot je cimetidin.
It is not intended to provide practical advice on how to use Fampyra. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
What are the risks associated with Fampyra? 
Kakšna tveganja so povezana z zdravilom Fampyra?
The side effects seen with Fampyra are mostly neurological (relating to the brain or nerves) and include seizures (fits), insomnia (difficulty sleeping), anxiety, problems with balance, dizziness, paraesthesia (unusual sensations like pins and needles), tremor, headache and asthenia (weakness). 
Neželeni učinki zdravila Fampyra so večinoma nevrološki (povezani z možgani ali živci) in vključujejo epileptične napade (krče), nespečnost, tesnobo, motnje ravnotežja, omotico, parestezijo (nenavadna občutja, kot zbadanje z iglami), tremor, glavobol in astenijo (šibkost).
What is Fampyra and what is it used for? 
Kaj je zdravilo Fampyra in za kaj se uporablja?
The most common side effect reported in clinical studies, affecting around 12% of the patients, is urinary tract infection. 
Najpogostejši neželeni učinek, o katerem so poročali v kliničnih študijah in ki se je pojavil pri približno 12 % bolnikov, je okužba sečil.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fampyra have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Fampyra upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
A third study in 633 patients measured improvements in walking ability over 24 weeks using a rating scale known as the multiple sclerosis walking scale (MSWS), where patients rated how well they were able to do various activities such as walking, running or climbing stairs. 
Tretja študija s 633 bolniki je merila izboljšanje sposobnosti hoje v 24 tednih z uporabo ocenjevalne lestvice, imenovane lestvica za ocenjevanje hoje pri multipli sklerozi (MSWS), pri kateri so bolniki ocenjevali, kako dobro lahko opravljajo različne dejavnosti, kot so hoja, tek ali hoja po stopnicah.
It must not be used in patients who have seizures or have ever had seizures or in patients with kidney problems. 
Ne smejo ga uporabljati bolniki, ki imajo ali so že imeli epileptične napade, in bolniki, ki imajo težave z ledvicami.
The active substance in Fampyra, fampridine, is a potassium channel blocker. 
Zdravilna učinkovina v zdravilu Fampyra, fampridin, je zaviralec kalijevih kanalčkov.
Fampyra is a medicine used to improve walking ability in adults with multiple sclerosis (MS) who have a walking disability. 
Fampyra je zdravilo, ki se uporablja za izboljšanje sposobnosti hoje pri odraslih z multiplo sklerozo (MS), ki ne morejo hoditi.
Why is Fampyra approved? 
Zakaj je bilo zdravilo Fampyra odobreno?
It contains the active substance fampridine. 
Vsebuje zdravilno učinkovino fampridin.
The European Medicines Agency therefore concluded that the benefits of Fampyra outweigh its risks for patients with a walking disability and recommended that it be given marketing authorisation. 
Evropska agencija za zdravila je zato sklenila, da koristi zdravila Fampyra odtehtajo z njim povezana tveganja pri bolnikih, ki ne morejo hoditi, in priporočila, da se zanj odobri dovoljenje za promet.
For more information about treatment with Fampyra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Fampyra preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The studies with Fampyra showed that the medicine is likely to benefit approximately one third of patients with MS who have a walking disability, and that patients benefiting from the treatment can be identified at an early stage allowing treatment to be stopped in other patients. 
Študije z zdravilom Fampyra so pokazale, da zdravilo verjetno koristi približno eni tretjini bolnikov z multiplo sklerozo z nezmožnostjo hoje ter da je že v zgodnji fazi zdravljenja mogoče ugotoviti, katerim bolnikom zdravilo koristi, kar omogoča, da se pri drugih bolnikih zdravljenje prekine.
It acts on damaged nerves, where it prevents charged potassium particles from leaving the nerve cells. 
Deluje na poškodovane živce, tako da preprečuje, da bi nabiti delci kalija zapustili živčne celice.
Two main studies in 540 patients with multiple sclerosis showed that Fampyra was more effective than placebo (a dummy treatment) at improving walking speed. 
Dve glavni študiji s 540 bolniki z multiplo sklerozo sta pokazali, da zdravilo Fampyra izboljša hitrost hoje učinkoviteje od placeba (zdravila brez zdravilne učinkovine).
For practical information about using Fampyra, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Fampyra naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
This is believed to have the effect of allowing the electrical impulse to continue travelling along the nerves to stimulate the muscles, making it easier to walk. 
To domnevno omogoča nadaljevanje pretoka električnih impulzov po živcih, kar zagotavlja stimulacijo mišic in bolnikom omogoča lažjo hojo.
How does Fampyra work? 
Kako zdravilo Fampyra deluje?
For the full list of all side effects reported with Fampyra, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Fampyra, glejte navodilo za uporabo.
In one of the studies 35% of patients taking Fampyra had higher walking speed on at least three out of four occasions than their quickest speed before treatment compared with 8% of patients taking placebo . 
V eni od študij je doseglo 35 % bolnikov, ki so jemali zdravilo Fampyra, višjo hitrost hoje, kot je bila njihova največja hitrost pred zdravljenjem, vsaj v treh od štirih primerov, v primerjavi z 8 % bolnikov, ki so jemali placebo.
In MS, this transmission of electrical impulses is impaired when the protective sheaths around the nerves become damaged, which can lead to muscle weakness, muscle stiffness and difficulty walking. 
Pri multipli sklerozi je prenos električnih impulzov okvarjen, ker je zaščitna ovojnica, ki obdaja živce, poškodovana, kar lahko povzroči mišično oslabelost, togost mišic in težave s hojo.
MS is a disease of the nerves, in which inflammation destroys the protective sheath around the nerves. 
Multipla skleroza je bolezen živčnega sistema, pri kateri vnetje uničuje zaščitno ovojnico, ki obdaja živce.
In the second study the results were similar, with 43% of patients in the Fampyra group surpassing their previous best speed on three out of four occasions, compared with 9% in the placebo group. 
V drugi študiji so bili rezultati podobni, najboljšo hitrost pa je v treh od štirih primerov preseglo 43 % bolnikov, ki so jemali zdravilo Fampyra, v primerjavi z 9 % bolnikov, ki so jemali placebo.
How is Fampyra used? 
Kako se zdravilo Fampyra uporablja?
In this study, 43% of patients taking Fampyra had at least an 8-point improvement in their MSWS score compared with 34% of those on placebo. 
V tej študiji je doseglo izboljšanje ocene MSWS vsaj za osem točk 43 % bolnikov, ki so jemali zdravilo Fampyra, v primerjavi s 34 % bolnikov, ki so jemali placebo.
For the body's muscles to contract, electrical impulses are transmitted along the nerves to the muscles. 
Telesne mišice se krčijo tako, da se po živcih do njih prenašajo električni impulzi.
The medicine can only be obtained with a prescription, and should be prescribed by a doctor experienced in treating MS. For further information, see the package leaflet. 
Predpisovanje in izdaja zdravila Fampyra je le na recept, predpisati pa ga mora zdravnik z izkušnjami z zdravljenjem multiple skleroze.
EU/2/10/112/001 BTVPUR AlSap 1 
EU/2/10/112/001 BTVPUR Alsap 1 Bluetongue virus serotip 1:
Suspension for injection. 
Suspenzija za injiciranje
Packaging Content Package size Withdrawal period 
Ovojnina Vsebina Velikost pakiranja
(*) equivalent to titre prior to inactivation (log10) 
(*) Ekvivalent titru pred inaktivacijo
Subcutaneous Type I glass bottle with butyl elastomere closure 
Ovce in govedo Subkutano Steklenička (steklo tipa I) z butil elastomerno zaporko
Invented Name 
Izmišljeno ime Jakost
Medicinal product no longer authorised 
Zdravilo nima veā dovoljenja za promet
Strength 
Karenca
Note: 
Opomba:
The product information may be subsequently updated by the Member State competent authorities, in liaison with the Reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC. 
Informacije o zdravilu lahko pristojni organi države članice v sodelovanju z referenčno državo članico naknadno dopolnijo, kot je primerno, v skladu s postopki iz Poglavja 4 Naslova III Direktive 2001/83/ES.
This product information is the outcome of the referral procedure to which this Commission decision relates. 
Te informacije o zdravilu so rezultat napotitvenega postopka, na katerega se nanaša ta sklep Komisije.
Product information 
Informacije o zdravilu
Annex III Product information 
Priloga III Informacije o zdravilu
The valid product information is the final version achieved during the Coordination group procedure. 
Veljavne informacije o zdravilu so končna različica, dogovorjena med postopkom skupine za usklajevanje.
This summary was last updated in 07-2016. 
Povzetek je bil nazadnje posodobljen 07-2016.
This study was extended to almost 4 years and confirmed the long-term benefits and safety of HyQvia. 
Ta študija je bila podaljšana na skoraj štiri leta, pri čemer so bile potrjene dolgoročne koristi in varnost zdravila HyQvia.
The European Commission granted a marketing authorisation valid throughout the European Union for HyQvia on 16 May 2013. 
Evropska komisija je dovoljenje za promet z zdravilom HyQvia, veljavno po vsej Evropski uniji, izdala 16. maja 2013.
The main measure of effectiveness was the number of serious bacterial infections that developed over one year of treatment. 
Glavno merilo učinkovitosti je bilo število resnih bakterijskih okužb, ki so se pojavile v enem letu zdravljenja.
IgG has been used as a medicine since the 1950s and has a wide range of activity against organisms that can cause infection. 
IgG se v medicini uporablja od petdesetih let preteklega stoletja in ima širok razpon delovanja proti organizmom, ki povzročajo okužbe.
It contains immunoglobulin G (IgG), which is a type of antibody. 
Vsebuje imunoglobulin G (IgG), ki je vrsta protitelesa.
What measures are being taken to ensure the safe and effective use of HyQvia? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila HyQvia?
The full EPAR for HyQvia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo HyQvia je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The study showed that HyQvia was able to reduce this number to 0.03 per year. 
Študija je pokazala, da se je z uporabo zdravila HyQvia število okužb zmanjšalo na 0,03 na leto.
This is a summary of the European public assessment report (EPAR) for HyQvia. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo HyQvia.
The dose and frequency of infusions (how often it is given) depend on the individual patient and may need to be adjusted depending on their response. 
Odmerek in pogostost infundiranja (pogostost dajanja zdravila) se določi za vsakega bolnika posebej in se ju po potrebi prilagodi glede na njegov odziv.
Other information about HyQvia 
Druge informacije o zdravilu HyQvia
The most common side effects with HyQvia (which may affect more than 1 in 10 people) are local reactions such as swelling and discomfort at the site of the infusion. 
Najpogostejši neželeni učinki zdravila HyQvia (ki lahko prizadenejo več kot 1 osebo od 10) so lokalne reakcije, kot so otekline in neprijeten občutek na mestu infundiranja.
HyQvia must not be given into a blood vessel or a muscle. 
Zdravila HyQvia se ne sme dajati v krvno žilo ali mišico.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of HyQvia have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo zdravila HyQvia, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.